financetom
Business
financetom
/
Business
/
PhonePe hits 250 mn user mark, registers 925 mn transactions in October
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PhonePe hits 250 mn user mark, registers 925 mn transactions in October
Nov 2, 2020 4:28 AM

Flipkart-owned fintech platform PhonePe on Monday said it has crossed the 250 million registered user milestone. The company reported over 100 million monthly active users (MAU) and 2.3 billion app sessions in October, a statement said. ”PhonePe had a record month in October, processing 925 million transactions – its highest so far – with an annual TPV (total payment volume) run rate of USD 277 billion. PhonePe also processed 835 million UPI transactions in October, for a market-leading share of over 40 percent,” it added.

Sameer Nigam, CEO and founder of PhonePe, said the company has set a target of crossing 500 million registered users by December 2022. ”In line with our brand ethos of ’Karte Ja. Badhte Ja’, we continue to launch new and innovative products for every strata of Indian society, as well as enable digital payment acceptance across every merchant in every village and town in India,” he added.

PhonePe – which competes with the likes of Paytm, MobiKwik and Google Pay – allows users to send and receive money, recharge mobile and make utility payments as well as buy gold and make investments. It had also launched its ’Switch’ platform that allows customers can place orders on over 220 apps including Ola, Myntra, IRCTC, Goibibo, RedBus and Oyo.

Also Read

: Paytm Postpaid aims to double postpaid service users to 1.5 cr by March 2021

PhonePe is accepted at 13 million merchant outlets across 500 cities nationally.

First Published:Nov 2, 2020 1:28 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment
Mar 14, 2024
05:38 PM EDT, 03/14/2024 (MT Newswires) -- Nuvation Bio ( NUVB ) said late Thursday the first patient has been dosed in a phase 1/2 study of NUV-1511 to treat advanced solid tumors. The company said the study will initially evaluate safety and tolerability, pharmacokinetic profile, and assess for indications of clinical activity in patients with advanced solid tumors who...
--Caleres Keeps Regular Quarterly Cash Dividend at $0.07 a Share, Payable April 12 to Holders of Record March 28
--Caleres Keeps Regular Quarterly Cash Dividend at $0.07 a Share, Payable April 12 to Holders of Record March 28
Mar 14, 2024
05:38 PM EDT, 03/14/2024 (MT Newswires) -- Price: 38.5, Change: +0.16, Percent Change: +0.42 ...
Madrigal Pharmaceuticals Gets FDA Approval for Liver Fibrosis Therapy
Madrigal Pharmaceuticals Gets FDA Approval for Liver Fibrosis Therapy
Mar 14, 2024
05:36 PM EDT, 03/14/2024 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) received the US Food and Drug Administration's accelerated approval of Rezdiffra for treating adults with noncirrhotic nonalcoholic steatohepatitis and moderate to advanced liver fibrosis, the company said Thursday. Rezdiffra, which is a once-daily oral therapy, was approved in combination with diet and exercise, the company said. The approval...
Getty Images Stock Climbs On Better-Than-Expected Q4 Revenue Results
Getty Images Stock Climbs On Better-Than-Expected Q4 Revenue Results
Mar 14, 2024
Getty Images Holdings Inc. ( GETY ) reported its fourth-quarter financial results after the bell Thursday. Here's a look at the details.  The Details: The company reported quarterly sales of $225.94 million which beat the analyst consensus estimate of $216.46 million by 4.38% and is a 2.39% decrease over sales of $231.47 million from the same period last year. Getty...
Copyright 2023-2026 - www.financetom.com All Rights Reserved